Stockreport

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

Radiopharm Theranostics Limited - American Depositary Shares  (RADX) 
PDF 177Lu-RAD202 demonstrated encouraging tumor uptake and a favorable safety profile in the lowest dose cohort  Data Safety and Monitoring Committee Recently Approved Adva [Read more]